Jean Filo

Jean Filo

Auto-generated profile, based on publicly available information

Jean Filo

Department of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Neurosurgery
Verified
Journal Article
Closed access
FRFelipe Ramirez-Velandia
Felipe Ramirez-Velandia
AEAlejandro Enriquez-Marulanda
Alejandro Enriquez-Marulanda
JFJean Filo
Jean Filo
MYMichael Young
Michael Young
TFThomas B. Fodor
Thomas B. Fodor
COChristopher S. Ogilvy
Christopher S. Ogilvy
BACKGROUND AND OBJECTIVES: The pipeline embolization device (PED) Flex with Shield technology is a third-generation flow diverter used for intracranial aneurysm treatment designed to decrease thrombogenicity through a phosphorylcholine coating. Herein, we aim to compare the rate of thromboembolic events in PED with Shield technology and PED without it through propensity score matching. METHODS: We conducted a retrospective analysis of aneurysms treated with PED first-generation/PED Flex and PED with Shield between 2013 and 2023 at a single academic institution. Patients were matched through propensity score by controlling for confounding factors including age, smoking history, diabetes, previous subarachnoid hemorrhage, modified Rankin Scale pretreatment, location, aneurysm size, previous treatment, and clopidogrel or aspirin resistance. After matching, we evaluated for periprocedural and postoperative thromboembolic events. Data analysis was performed using Stata 14. RESULTS: A total of 543 patients with 707 aneurysms treated in 605 procedures were included in the analysis. From these, 156 aneurysms were treated with PED with Shield (22.07%) and 551 (77.93%) without Shield technology. Propensity score matching resulted in 84 matched pairs. The rate of thromboembolic events was 3.57% for PED Shield and 10.71% for PED first-generation/PED Flex (P = .07), while retreatment rates were 2.38% for PED Shield and 8.32% for PED Flex (P = .09). Complete occlusion at first (P = .41) and last imaging follow-up (P = .71), in-stent stenosis (P = .95), hemorrhagic complications (P = .31), and functional outcomes (P = .66) were comparable for both groups. CONCLUSION: This is the first study in the literature performing a propensity scored–matched analysis comparing PED with PED with Shield technology. Our study suggests a trend toward lower thromboembolic events for PED Shield, even after controlling for aspirin and clopidogrel resistance, and a trend toward lower aneurysm retreatment rates with PED Shield, without reaching statistical significance.

21 January 2024 in World Neurosurgery
Verified
Journal Article
Closed access
SPSamuel D Pettersson
Samuel D Pettersson
PSPaulina Skrzypkowska
Paulina Skrzypkowska
KPKrzysztof Pietrzak
Krzysztof Pietrzak
AOAleksander Och
Aleksander Och
KSKamil Siedlecki
Kamil Siedlecki
Grzegorz MiekisiakGrzegorz Miekisiak
Grzegorz Miekisiak

2 August 2024 in World Neurosurgery
Verified
Journal Article
Closed access
FRFelipe Ramirez-Velandia
Felipe Ramirez-Velandia
AEAlejandro Enriquez-Marulanda
Alejandro Enriquez-Marulanda
JFJean Filo
Jean Filo
TFThomas B. Fodor
Thomas B. Fodor
DSDaniel Sconzo
Daniel Sconzo
COChristopher S. Ogilvy
Christopher S. Ogilvy

25 March 2024 in World Neurosurgery
Verified
Journal Article
Closed access
SPSamuel D. Pettersson
Samuel D. Pettersson
MEMohamed K. Elrafie
Mohamed K. Elrafie
JMJakub Makarewicz
Jakub Makarewicz
Tomasz KlepinowskiTomasz Klepinowski
Tomasz Klepinowski
PSPaulina Skrzypkowska
Paulina Skrzypkowska
COChristopher S. Ogilvy
Christopher S. Ogilvy

10 September 2024 in World Neurosurgery
Verified
Journal Article
Closed access
OAOmar Alwakaa
Omar Alwakaa
AEAlejandro Enriquez-Marulanda
Alejandro Enriquez-Marulanda
FRFelipe Ramirez-Velandia
Felipe Ramirez-Velandia
JFJean Filo
Jean Filo
EMEmmanuel Mensah
Emmanuel Mensah
COChristopher S. Ogilvy
Christopher S. Ogilvy

19 June 2024 in World Neurosurgery
Verified
Journal Article
Closed access
JFJean Filo
Jean Filo
MSMira Salih
Mira Salih
OAOmar Alwakaa
Omar Alwakaa
FRFelipe Ramirez-Velandia
Felipe Ramirez-Velandia
MSMax Shutran
Max Shutran
COChristopher S. Ogilvy
Christopher S. Ogilvy